Device Trial Radar · NCT00121485
Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Destination Therapy
Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
200
Actual
Start
Feb 2005
Primary completion
Jun 2009
Study completion Jan 2012
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- Collaborators
- Thoratec Corporation
- First posted
- Jul 21, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and effectiveness of the Thoratec HeartMate II Left Ventricular Assist System (LVAS) as Destination Therapy in end-stage heart failure patients who do not qualify for cardiac transplantation. The Destination Therapy indication for use was approved by FDA on January 20, 2010 (ref. PMA P060040/S005).
Conditions
- Heart Failure, Congestive
- Ventricular Dysfunction
- Cardiomyopathies
Interventions
Left Ventricular Assist System (LVAS)Device
Implantation of left ventricular assist device for hemodynamic support
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite EndpointTime frame: Patients' status at 2 years post-implant
Locations
47 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Hospital
Phoenix, Arizona
Sharp Memorial Hospital
San Diego, California
44 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.